KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Debt to Equity: 2011-2021

Historic Debt to Equity for TherapeuticsMD (TXMD) over the last 6 years, with Dec 2021 value amounting to -$2.01.

  • TherapeuticsMD's Debt to Equity rose 40.44% to -$1.94 in Q3 2022 from the same period last year, while for Sep 2022 it was -$11.92, marking a year-over-year increase of 19.78%. This contributed to the annual value of -$2.01 for FY2021, which is 4.91% down from last year.
  • As of FY2021, TherapeuticsMD's Debt to Equity stood at -$2.01, which was down 4.91% from -$1.92 recorded in FY2020.
  • In the past 5 years, TherapeuticsMD's Debt to Equity registered a high of $21.15 during FY2019, and its lowest value of -$2.01 during FY2021.
  • Its 3-year average for Debt to Equity is $5.74, with a median of -$1.92 in 2020.
  • As far as peak fluctuations go, TherapeuticsMD's Debt to Equity skyrocketed by 2,711.34% in 2019, and later crashed by 109.06% in 2020.
  • Yearly analysis of 4 years shows TherapeuticsMD's Debt to Equity stood at $0.75 in 2018, then surged by 2,711.34% to $21.15 in 2019, then slumped by 109.06% to -$1.92 in 2020, then fell by 4.91% to -$2.01 in 2021.